Dr. Packiam is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
195 Little Albany Street
New Brunswick, NJ 08903Phone+1 732-235-2465
Summary
- Vignesh Packiam, MD received his medical degree from the University of Pittsburgh, followed by residency at the University of Chicago, and a two-year Society of Urologic Oncology accredited fellowship at Mayo Clinic. Dr. Packiam treats genitourinary malignancies including bladder, prostate, kidney, and testicular cancer, and is experienced in open and robotic surgery. He has a background in clinical trials and feels it is important to educate his patients about all available options. He has a clinical interest in bladder cancer and supports patient centered groups such as the Bladder Cancer Advocacy Network. He is an active member of numerous cancer societies, serves as a reviewer for multiple urology journals, and has authored over 100 peer-reviewed articles and book chapters.
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Minimally Invasive Urologic Surgery, 2018 - 2020
- University of ChicagoResidency, Urology, 2012 - 2018
- University of Pittsburgh School of MedicineClass of 2012
- University of Wisconsin-MadisonB.S., Biology, Philosophy, Dean's Scholar, 2004 - 2008
Certifications & Licensure
- IA State Medical License 2020 - 2025
- NJ State Medical License 2023 - 2025
- MN State Medical License 2018 - 2021
- WI State Medical License 2018 - 2021
- IL State Medical License 2015 - 2020
- American Board of Urology Urology
Publications & Presentations
PubMed
- Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive N...Jacob Taylor, Ashish M Kamat, Drupad Annapureddy, Zine-Eddine Khene, Jeffrey Howard
European Urology Oncology. 2025-04-01 - Rethinking the definition of stage III disease in adrenocortical carcinoma: Assessing the impact of clinical lymph node positive disease.Benjamin J Lichtbroun, Helen Gao, Kevin Chua, John Pfail, Rachel Passarelli
Urologic Oncology. 2025-04-01 - Assessing the efficacy and safety of sequential intravesical gemcitabine and docetaxel - does time from transurethral resection of bladder tumour to induction matter?Ian M McElree, Grant M Henning, Ryan L Steinberg, Helen Y Hougen, Sarah L Mott
BJU International. 2025-03-21
Press Mentions
- Gemcitabine-Docetaxel Effective Alternative to BCG in NMIBCMarch 7th, 2023
- Combination Chemotherapy May Be Safe and Effective Alternative for the Treatment of Patients with Non–Muscle-Invasive Bladder Cancer Amid BCG ShortageMarch 1st, 2023
- Given the Lack of Standard BCG Treatments Worldwide, an Alternative Bladder Cancer Treatment Is EvolvingFebruary 28th, 2023
- Join now to see all
External Links
- Websitehttps://www.cinj.org/vignesh-t-packiam-md
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: